Can-Fite BioPharma Ltd.CANFNYSE
LOADING
|||
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -19.39% | -8.67% | +15.48% | -36.08% | -36.08% |
| Gross Profit Growth | -19.39% | -8.67% | +15.48% | -36.08% | -36.08% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +48.58% | +106.56% | +70.52% | +87.43% | +87.43% |
| Weighted Average Shares Diluted Growth | +48.64% | +106.55% | +70.53% | +87.33% | +87.33% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -2224.21% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -2226.31% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | -1.28% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -46.32% | -0.53% | -8.70% | +30.36% | +30.36% |
| Book Value per Share Growth | -75.73% | -49.73% | -48.94% | -9.95% | -9.95% |
| Debt Growth | -13.64% | +103.92% | +160.00% | +57.89% | +57.89% |
| R&D Expense Growth | +6.42% | +10.55% | +13.34% | +5.13% | +5.13% |
| SG&A Expenses Growth | +22.20% | -0.13% | +5.40% | +35.48% | +35.48% |